Verrica Pharmaceuticals Inc. (VRCA) Form 8-K — May 12, 2026
Verrica Pharmaceuticals Inc. reported strong financial results for the first quarter of 2026, with total revenue of $5.0 million, including U.S. YCANTH net product revenue of $4.3 million, up 16.2% over the previous quarter and 25.4% year-over-year. The company also announced significant progress in its clinical trials, achieving over 50% of the current targeted enrollment in the first trial of the global Phase 3 program for common warts, with the second trial expected to initiate in mid-2026.
Key figures
- Revenue
- 5023
- Total Debt
- 5814
- Revenue Yoy
- 25.4
- Cash Position
- 20600
- Shares Outstanding
- 21305025
Price after filing
Close on the filing date to close N calendar days later (from $7.15). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.